Mathers Edward T. - 03 Jun 2026 Form 4 Insider Report for Trevi Therapeutics, Inc. (TRVI)

Reporting relationship: Director
Issuer ticker: TRVI
Reported as of: 03 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Jun 2026, 16:28:16 UTC
Prior SEC filing: 16 Mar 2026
Next SEC filing: 08 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Zachary Bambach, attorney-in-fact

Key filing fact

Mathers Edward T. filed Form 4 for Trevi Therapeutics, Inc. (TRVI) on 04 Jun 2026.

Key facts

This page summarizes Mathers Edward T.'s Form 4 filing for Trevi Therapeutics, Inc. (TRVI).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Jun 2026, 16:28.

Change

Previous filing in this sequence was filed on 16 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001328625 Primary reporting owner

Mathers Edward T

Relationship: Director
Address: 104 5TH AVE, 19TH FLOOR, NEW YORK
Signature: /s/ Zachary Bambach, attorney-in-fact
Signature date: 04 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TRVI transaction Derivative

Nonstatutory Stock Option (right to buy)

Award

Transaction value
Shares: +35,000
Change %
Price: $0.000000^*
Shares after: 35,000
Date: 03 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 35,000
Exercise price: $13.45
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option was granted on June 3, 2026. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer.